Aflibercept Onestep ELISA Kit

Aflibercept (marketed under brand names such as EYLEA® and ZALTRAP®) is an injectable prescription medicine classified as a VEGF (Vascular Endothelial Growth Factor) inhibitor. It functions as a recombinant fusion protein, essentially acting as a "VEGF trap." Its mechanism involves binding to VEGF-A and placental growth factor (PlGF) with high affinity. By doing so, it blocks their interaction with natural VEGF receptors. This inhibition prevents the growth of new, leaky blood vessels (angiogenesis) and decreases vascular permeability, which is a key factor in reducing fluid accumulation (edema). Aflibercept is primarily used in ophthalmology to treat neovascular (wet) Age-related Macular Degeneration (AMD), macular edema following Retinal Vein Occlusion (RVO), and Diabetic Macular Edema (DME). It is also used in oncology, in combination with chemotherapy, for certain types of metastatic colorectal cancer. The drug is administered directly into the eye (intravitreal injection) for retinal conditions and intravenously for cancer treatment. Its therapeutic effect helps to stabilize and often improve vision in eye diseases by controlling the abnormal blood vessel growth and leakage that cause damage to the retina.